• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部治疗对分化型甲状腺癌远处转移的有效性

Usefulness of local therapy for distant metastases of differentiated thyroid cancer.

作者信息

Moritani Sueyoshi, Takenobu Masao, Yasunaga Masakazu, Fujii Taihei, Kitano Hiroya

出版信息

Eur Thyroid J. 2025 Jun 11;14(3). doi: 10.1530/ETJ-24-0237. Print 2025 Jun 1.

DOI:10.1530/ETJ-24-0237
PMID:40435159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12160455/
Abstract

OBJECTIVE

Treatment for distant metastases (DM) of differentiated thyroid cancer (DTC) aims to improve the prognosis and quality of life (QOL). Radioactive iodine and molecular targeted therapies are the primary systemic treatments for DM. Combining these with local treatments, such as surgery and radiotherapy targeting metastatic sites, may provide additional benefits to systemic therapy.

METHODS

This study reviewed the additional effects of local therapies on common metastatic sites of DTC, such as pulmonary or bone metastases (BM), the efficacy of bone-modifying agents (BMAs) for BM, and the therapeutic effects of local treatments for less common brain metastases.

RESULTS

Although based on retrospective studies with no definitive conclusions on the effectiveness of each treatment, local therapy for DM in DTC patients has been shown to enhance prognosis and QOL in several studies. Considering the results of clinical trials for metastatic tumors, local therapy for one or a few pulmonary or BM in DTC should be considered, if expected to improve prognosis and QOL. Surgical intervention is recommended for spinal metastases presenting with spinal compression symptoms or for long BM in extremities at risk of pathological or impending fractures. BMAs are also recommended to reduce the risk of skeletal-related events. Surgery, stereotactic radiotherapy, and whole-brain radiotherapy are suggested for brain metastases to improve the prognosis and QOL.

CONCLUSION

Incorporating local therapy alongside systemic treatment can enhance the prognosis and QOL and should be considered a viable treatment option.

摘要

目的

分化型甲状腺癌(DTC)远处转移(DM)的治疗旨在改善预后和生活质量(QOL)。放射性碘和分子靶向治疗是DM的主要全身治疗方法。将这些方法与局部治疗(如针对转移部位的手术和放疗)相结合,可能会为全身治疗带来额外益处。

方法

本研究回顾了局部治疗对DTC常见转移部位(如肺或骨转移(BM))的附加效果、骨改良剂(BMA)对BM的疗效以及局部治疗对较少见的脑转移的治疗效果。

结果

尽管基于回顾性研究,对每种治疗的有效性尚无定论,但在一些研究中已表明,DTC患者DM的局部治疗可改善预后和生活质量。考虑到转移性肿瘤的临床试验结果,如果预期能改善预后和生活质量,对于DTC中一处或少数几处肺或BM转移应考虑局部治疗。对于出现脊髓压迫症状的脊柱转移或四肢有发生病理性骨折或即将发生骨折风险的长BM转移,建议进行手术干预。还建议使用BMA以降低骨相关事件的风险。对于脑转移,建议进行手术、立体定向放疗和全脑放疗以改善预后和生活质量。

结论

将局部治疗与全身治疗相结合可改善预后和生活质量,应被视为一种可行的治疗选择。

相似文献

1
Usefulness of local therapy for distant metastases of differentiated thyroid cancer.局部治疗对分化型甲状腺癌远处转移的有效性
Eur Thyroid J. 2025 Jun 11;14(3). doi: 10.1530/ETJ-24-0237. Print 2025 Jun 1.
2
Improved Survival After Multimodal Approach with I Treatment in Patients with Bone Metastases Secondary to Differentiated Thyroid Cancer.分化型甲状腺癌骨转移患者采用碘治疗的多模式方法后生存改善。
Thyroid. 2019 Jul;29(7):971-978. doi: 10.1089/thy.2018.0582. Epub 2019 May 30.
3
Brain Metastases in Differentiated Thyroid Cancer: Clinical Presentation, Diagnosis, and Management.分化型甲状腺癌脑转移:临床表现、诊断与治疗。
Thyroid. 2024 Oct;34(10):1194-1204. doi: 10.1089/thy.2024.0240. Epub 2024 Sep 4.
4
Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy.全甲状腺切除及放射性碘治疗后分化型甲状腺癌远处高功能转移患者的临床管理及结局
Thyroid. 2015 Feb;25(2):229-37. doi: 10.1089/thy.2014.0233. Epub 2014 Nov 19.
5
Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.评估伴有远处转移的分化型甲状腺癌患者与癌症特异性生存相关的预后因素。
Ann Surg Oncol. 2013 Apr;20(4):1329-35. doi: 10.1245/s10434-012-2711-x. Epub 2012 Oct 28.
6
Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues.分化型甲状腺癌骨转移:现状与问题
J Endocrinol Invest. 2021 Mar;44(3):403-419. doi: 10.1007/s40618-020-01374-7. Epub 2020 Aug 3.
7
Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.分化型甲状腺癌出现不少于三个远处器官系统转移患者的临床转归和预后因素。
Endocrine. 2019 Nov;66(2):254-265. doi: 10.1007/s12020-019-01999-6. Epub 2019 Jul 17.
8
LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES.分化型甲状腺癌伴骨转移患者的长期预后和预测因素。
Endocr Pract. 2019 May;25(5):427-437. doi: 10.4158/EP-2018-0465. Epub 2019 Jan 18.
9
[Distant metastasis of differentiated thyroid cancers. Diagnosis by 131 iodine (I 131) and treatment].[分化型甲状腺癌的远处转移。通过131碘(I 131)诊断及治疗]
Ann Endocrinol (Paris). 1995;56(3):205-8.
10
Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors.分化型甲状腺癌初诊时伴远处转移的临床结局和预后因素。
Ann Surg. 2010 Jan;251(1):114-9. doi: 10.1097/SLA.0b013e3181b7faf6.

本文引用的文献

1
Disease-Specific Survival Trends for Patients Presenting with Differentiated Thyroid Cancer and Distant Metastases in the United States, 1992-2018.美国 1992-2018 年分化型甲状腺癌伴远处转移患者的疾病特异性生存趋势。
Thyroid. 2023 Jan;33(1):63-73. doi: 10.1089/thy.2022.0353. Epub 2022 Nov 18.
2
Mid and long-term overall survival after carcinologic resections of thyroid cancer bone metastases.甲状腺癌骨转移癌切除术后的中长期总体生存率。
Front Surg. 2022 Jul 12;9:965951. doi: 10.3389/fsurg.2022.965951. eCollection 2022.
3
Dabrafenib Versus Dabrafenib + Trametinib in -Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.达拉非尼对比达拉非尼联合曲美替尼治疗放射性碘难治性分化型甲状腺癌(BRAF V600E 突变阳性):一项随机、开放标签、多中心、2 期临床试验的结果。
Thyroid. 2022 Oct;32(10):1184-1192. doi: 10.1089/thy.2022.0115. Epub 2022 Jul 5.
4
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.拉罗替尼治疗TRK融合阳性甲状腺癌患者的疗效与安全性。
Eur J Endocrinol. 2022 Apr 29;186(6):631-643. doi: 10.1530/EJE-21-1259.
5
Radiotherapy for Brain Metastases from Thyroid Cancer: An Institutional and National Retrospective Cohort Study.甲状腺癌脑转移的放射治疗:一项机构和全国回顾性队列研究。
Thyroid. 2022 Jul;32(7):781-788. doi: 10.1089/thy.2021.0628. Epub 2022 Jun 6.
6
Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival.分化型甲状腺癌的骨转移:放射性碘治疗的肿瘤异质性反应与总体生存。
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2401-2413. doi: 10.1007/s00259-022-05697-w. Epub 2022 Feb 12.
7
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.恩曲替尼治疗 NTRK 融合阳性实体瘤患者的疗效和安全性的更新综合分析。
Clin Cancer Res. 2022 Apr 1;28(7):1302-1312. doi: 10.1158/1078-0432.CCR-21-3597.
8
Brain Metastases From Differentiated Thyroid Carcinoma: A Retrospective Study of 22 Patients.分化型甲状腺癌脑转移回顾性研究:22 例患者分析
Front Endocrinol (Lausanne). 2021 Sep 16;12:730025. doi: 10.3389/fendo.2021.730025. eCollection 2021.
9
Spinal metastases from thyroid cancer: Some prognostic factors.甲状腺癌脊柱转移:一些预后因素。
Eur J Surg Oncol. 2022 Jan;48(1):292-298. doi: 10.1016/j.ejso.2021.09.001. Epub 2021 Sep 4.
10
Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials.比较地舒单抗和唑来膦酸治疗实体瘤和多发性骨髓瘤伴骨转移:基于随机对照试验的系统评价和荟萃分析。
J Orthop Surg Res. 2021 Jun 22;16(1):400. doi: 10.1186/s13018-021-02554-8.